OptiNose
$3.459876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$3.45
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
$0.00 (0.00%) Today
-$0.06 (-1.71%) As of 1:00 AM UTC after-hours
Why Robinhood?
You can buy or sell OptiNose and other stocks, options, and ETFs commission-free!
About OPTN
OptiNose, Inc. operates as a pharmaceutical company. The firm engages in the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists. Its products include the XHANCE and ONZETRA Xsail. The company was founded by Per Gisle Djupesland and Helena Kyttari Djupesland in October 2000 and is headquartered in Yardley, PA. The listed name for OPTN is OptiNose, Inc. Common Stock.
CEO
Peter Kaighn Miller
Employees
204
Headquarters
Yardley, Pennsylvania
Founded
2000
Market Cap
201.72M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
708.05K
High Today
$3.59
Low Today
$3.31
Open Price
$3.50
Volume
656.04K
52 Week High
$10.00
52 Week Low
$3.14
OPTN News
BenzingaMar 3
Recap: OptiNose Q4 Earnings
Shares of OptiNose (NASDAQ:OPTN) decreased 0.8% in pre-market trading after the company reported Q4 results.
Quarterly Results
Earnings per share rose 20.69%
OPTN Earnings
-$0.74
-$0.64
-$0.53
-$0.43
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
-$0.46 per share
Actual
-$0.46 per share